Addex Therapeutics Ltd
ADXNHealthcare|Biotechnology|CH
$2.90
+0.00 (+0.00%)
DCF Value
$1.41
Tangible Book / Share
$1.31
Cash / Share
$0.53
Clinical Trials (8)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT04857359 Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy | Parkinson Disease, Dyskinesia, Drug-Induced | P2P3 | Terminated | 25 | RCT, Double-blind | Dipraglurant, Placebo |
| NCT05116813 Open-label Safety Study of Dipraglurant (ADX48621) in Patients With Parkinson's Disease Receiving Levodopa-based Therapy | Parkinson Disease, Dyskinesia, Drug-Induced | P2P3 | Terminated | 17 | Open-label | Dipraglurant |
| NCT00820079 ADX10059 as a Monotherapy in Patients With Gastroesophageal Reflux (GERD) | Gastroesophageal Reflux | P2 | Completed | 120 | RCT, Double-blind | ADX10059, ADX10059 Matching Placebo |
| NCT01336088 ADX48621 for the Treatment of Levodopa Induced Dyskinesia in Patients With Parkinson's Disease | Parkinson's Disease | P2 | Completed | 83 | RCT, Double-blind | ADX48621, Placebo |
| NCT00810485 ADX10059 as an add-on Therapy to Proton Pump Inhibitors (PPIs) in Patients With Gastroesophageal Reflux (GERD) | Gastroesophageal Reflux | P2 | Completed | 298 | RCT, Double-blind | ADX10059, ADX10059, ADX10059, ADX10059 Matching Placebo |
| NCT00820105 ADX10059 Migraine Prevention Study | Migraine | P2 | Terminated | 350 | RCT, Double-blind | ADX10059, ADX10059, ADX10059, ADX10059 Matching Placebo |
| NCT05027997 Exploratory Study of Dipraglurant (ADX48621) for the Treatment of Patients With Blepharospasm | Blepharospasm, Dystonia | P2 | Completed | 15 | RCT, Double-blind | Dipraglurant, Placebo |
| NCT02447640 PET Imaging Study to Evaluate the mGlu5r Occupancy Following ADX48621 (Dipraglurant) Administration | Healthy | P1 | Completed | 12 | Open-label | ADX48621 |